RecruitingNCT06597526
The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
The Role of 18F-FDG & 68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastatic
Sponsor
Ruijin Hospital
Enrollment
30 participants
Start Date
Jun 15, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to investigate the value of 18F-FDG\&68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of people with peritoneal metastases from gastric cancer.
Eligibility
Min Age: 18 Years
Inclusion Criteria8
- Histologically confirmed gastric adenocarcinoma with no history of resection of primary or metastatic lesions
- Peritoneal metastases of gastric cancer requiring laparoscopy for definitive diagnosis without gastric outflow tract obstruction and intestinal obstruction
- Patients voluntarily enrolled in this study by signing an informed consent form
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) score ≤ 2,
- Expected life expectancy ≥ 3 months
- Adequate organ and bone marrow function
- Willingness to adhere to the study protocol and follow-up programme
Exclusion Criteria4
- Signs of distant metastases other than peritoneal metastases at enrolment
- Pregnant or breastfeeding women.
- Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix
- Severe mental disease, uncontrolled epilepsy, or central nervous system disease
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06597526
Related Trials
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
NCT072774391 location
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
NCT051871821 location
Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria
NCT074811102 locations
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT0692192817 locations
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT0570222944 locations